Unity Biotechnology
0 FOLLOWERS
UNITY is making medicines that target the root cause of age-related diseases. We make small things that do big things.
Unity Biotechnology
4d ago
SOUTH SAN FRANCISCO, Calif. , April 15, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended December 31, 2023 ..read more
Unity Biotechnology
2M ago
SOUTH SAN FRANCISCO, Calif. , Feb. 06, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced new research published in the peer-reviewed journal Nature Medicine that ..read more
Unity Biotechnology
4M ago
Topline 16-week data expected in the fourth quarter of 2024 SOUTH SAN FRANCISCO, Calif. , Dec. 12, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the first ..read more
Unity Biotechnology
5M ago
SOUTH SAN FRANCISCO, Calif. , Nov. 13, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2023 ..read more
Unity Biotechnology
5M ago
SOUTH SAN FRANCISCO, Calif. , Nov. 10, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY” or the “Company”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced the entry into a definitive agreement for the immediate ..read more
Unity Biotechnology
7M ago
Patients on combination treatment with UBX1325 and aflibercept from weeks 24-48 maintained vision gains achieved at week 24 on aflibercept alone, with greater vision improvement in patients with more severe disease Patients with prior anti-VEGF treatment and switched to UBX1325 monotherapy at study ..read more
Unity Biotechnology
9M ago
SOUTH SAN FRANCISCO, Calif. , Aug. 08, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the second quarter ended June 30, 2023 ..read more
Unity Biotechnology
1y ago
UBX1325 monotherapy did not achieve non-inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain in the anti-VEGF control arm UBX1325 maintained visual acuity in patients with ongoing active disease through 24 weeks with less than one letter mean decrease from baseline 52% of ..read more
Unity Biotechnology
1y ago
-Investor call with retinal expert Robert B. Bhisitkul , M.D., Ph.D., to be held on Tuesday, February 14, 2023 at 7:00 a.m. PT / 10:00 a.m. ET - -Complete 16- and 24-week safety and efficacy data from phase 2 ENVISION study in wet AMD expected in Q1 2023- SOUTH SAN FRANCISCO, Calif. , Feb ..read more
Unity Biotechnology
1y ago
SOUTH SAN FRANCISCO, Calif. , Jan. 18, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from January 3, 2023 , through January 17, 2023 , the Compensation ..read more